We recently compiled a list of the 15 Stocks That Will Go to The Moon According to Analysts. In this article, we are going to ...

Fintel reports that on February 28, 2025, Goldman Sachs initiated coverage of Summit Therapeutics (NasdaqGM:SMMT) with a Buy ...

We recently published a list of 12 Best Growth Stocks to Invest In According to Analysts. In this article, we are going to ...

We recently published a list of 10 Stocks Drop The Most Amid Investor Caution. In this article, we are going to take a look ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Goldman Sachs initiated coverage of Summit Therapeutics (SMMT) with a Buy rating and $42 price target Discover the Best Stocks and Maximize ...

SMMT stock opened at $20.69 on Friday. The company’s 50-day simple moving average is $19.99 and its 200 day simple moving average is $19.25. Summit Therapeutics has a 52 week low of $2.10 and a ...

Goldman Sachs analyst Salveen Richter initiated coverage of Summit Therapeutics (SMMT) with a Buy rating and $42 price target a Summit’s lead ...

Summit Therapeutics (NASDAQ:SMMT – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC ...

Summit Therapeutics established a clinical trial collaboration with Pfizer to develop ivonescimab for NSCLC and solid tumors.

UK vehicle producers face a perfect storm of global trade uncertainty, challenging manufacturing conditions and a market ...

Fintel reports that on February 28, 2025, Goldman Sachs initiated coverage of Summit Therapeutics (NasdaqGM:SMMT) with a Buy recommendation. As of February 19, 2025, the average one-year price ...